Galderma is investing over two billion Swedish Kronor in a new facility to meet the increasing global demand for Injectable Aesthetic products and provide additional capacity for new products in development.
The new site, set to be completed by the end of 2024, will be a state-of-the-art facility with initial production lines covering next-generation injectable aesthetics and other biologics. The factory will be built by the Swedish company KeyPlants with a modular design that will allow for easy expansion in the future.
Uppsala is one of Galderma’s flagship global manufacturing sites. We have a long heritage in here, and the region is world-renowned as a place with a top talent pool and a favorable business climate supporting manufacturing operations.
In 2022, the global Injectable Aesthetics market segment continues to show robust growth. With its continued commitment to innovation and broad channel exposure, Galderma is well positioned to capitalize on this growing consumer demand. In the first half of 2022, Galderma’s net sales in Aesthetics grew by 32% year-on-year on a constant currency basis, driven by balanced contributions across our premium cutting-edge brands.
Given Galderma’s robust growth and expansion – particularly in Injectable Aesthetics - as well as our Uppsala team’s continuous ability to set the highest standards in safety, quality and efficiency, we anticipate a very bright future for our operations here.